BoRich Bio Secures Over RMB 100 Million in Pre-A Financing to Accelerate Global Layout of Biopharmaceutical Quality and Safety Testing

VCBeat’s New Medicine was the first to learn that,BRC BIOTECHNOLOGY (SHANGHAI) CO., LTD. (“BRC BIOTECHNOLOGY”), a professional provider of biosafety testing services, recently completed a Pre-A financing round exceeding RMB 100 million. The round was led by Legend Capital, with participation from multiple other funds.The proceeds from this financing round will primarily be used to accelerate the expansion of GMP-compliant biosafety testing platforms, continuously refine the high-quality biosafety industry layout, and empower the quality and safety of domestic biopharmaceuticals. In less than a year, BRC BIOTECHNOLOGY has completed cumulative financing of nearly RMB 200 million.

Upholding the service philosophy of “science,” “safety,” “efficiency,” and “compliance,” BRC BIOTECHNOLOGY has created the “China speed” in biosafety testing services.Since its establishment in June 2022, the company has completed the construction, validation, and commissioning of a ~6,000 m² testing service platform that complies with Chinese, U.S., and European cGMP standards as well as Biosafety Level 2 (BSL-2) requirements, achieving the “100-Day Project” objectives.As of press time, BRC BIOTECHNOLOGY has successfully obtained certifications including ISO 9001:2015, CMA, BSL-1, and BSL-2 compliance qualifications, and has passed compliance audits conducted by dozens of leading domestic and international biopharmaceutical companies.

BRC BIOTECHNOLOGY’s proprietary platform has completed the development and compliance validation of hundreds of analytical methods, with several patent applications filed. It provides comprehensive biosafety testing solutions for a wide range of therapeutic modalities, including antibody drugs, vaccines, nucleic acid therapeutics, stem cell products, and cell and gene therapies. Committed to its mission of “ensuring the quality and safety of biopharmaceuticals,”BRC BIOTECHNOLOGY has secured tens of millions of yuan in orders over the past three months, completing the delivery of several IND and overseas BLA projects.

In addition, as a professional service provider with a global perspective, BRC BIOTECHNOLOGY has established strategic partnerships, including an exclusive collaboration in China with the Dutch testing company Cergentis and a strategic alliance with SGS Life Sciences for Northeast Asia. These strong alliances enable the delivery of superior technology and services to the market and customers, while accelerating overseas deployment and expansion into international markets. While comprehensively building a high-performance local service platform, BRC BIOTECHNOLOGY is enhancing its international influence, supporting the high-quality development of the biopharmaceutical industry, and safeguarding clinical medication and patient health.

Dr. Liu Haiyang, CEO of BRC BIOTECHNOLOGY, stated:“We are deeply honored to receive the recognition and support of Legend Capital for BRC BIOTECHNOLOGY. Although BRC BIOTECHNOLOGY was established only recently, its platform and team have rapidly gained market recognition and entered the global spotlight, leveraging years of industry accumulation, robust operational capabilities, and profound technical reserves. Our mission is to ensure the quality and safety of biopharmaceutical products and provide customers with the highest quality services. The professional operational and execution capabilities of BRC BIOTECHNOLOGY have been fully demonstrated in the post-pandemic era. We thank our investors and partners for their support of BRC BIOTECHNOLOGY. We will continue to focus on the development of novel testing technologies and the expansion of our platform’s testing capabilities. Rooted in China and covering the globe, BRC BIOTECHNOLOGY actively promotes collaboration with industry experts and partners. Upholding integrity, professionalism, and diligence, we are confident and capable of better empowering the sustained and rapid development of the biopharmaceutical industry.”

Legend Capital stated:“Biopharmaceuticals have achieved breakthrough progress across multiple disease areas, leading a multi-billion-dollar pharmaceutical market in recent years. The inherent characteristics of biopharmaceuticals, coupled with the complexity of their manufacturing processes, pose new challenges to their safety. High-quality biosafety testing for biopharmaceuticals provides comprehensive and direct assurance of patient medication safety, holding significant strategic importance for building China’s innovative ecosystem for biopharmaceuticals. The team at BRC BIOTECHNOLOGY has been deeply engaged in the field of biosafety testing for biopharmaceuticals for many years. It is well-versed in various biopharmaceutical manufacturing processes and thoroughly understands the safety testing requirements involved in regulatory filings and production, having accumulated extensive experience in biosafety testing. BRC BIOTECHNOLOGY has established a quality compliance system aligned with global standards and delivered excellent innovative service capabilities, securing its leading position in the field of biosafety quality control. We are honored to lead this round of financing and witness the rapid development of such a groundbreaking company with high growth potential. Legend Capital will continue to support BRC BIOTECHNOLOGY in accelerating the market expansion and industrial layout of its biosafety testing platform. We are confident that, under the leadership of its founding team, BRC BIOTECHNOLOGY will better facilitate the translation of biopharmaceutical innovations and ensure quality and safety, both in China and globally.”

About BRC BIOTECHNOLOGY

BRC BIOTECHNOLOGY specializes in compliance-focused quality testing services for biological drugs. Headquartered at the Free Trade Zone No. 1 Bio-Industrial Park in Waigaoqiao, Shanghai, the company has established a 6,000-square-meter testing service platform, commercial office space, and training center that comply with cGMP and BSL-2 standards. Its biological drug evaluation system meets international quality standards, supporting quality assessments for biologics, cell and gene therapies, nucleic acid drugs, vaccines, and other biological products. Committed to addressing the urgent needs of biosafety testing, BRC BIOTECHNOLOGY serves as your partner in ensuring the quality and safety of biological drugs. We provide world-class local services to safeguard China’s biopharmaceutical safety and accelerate the regulatory approval and market launch of innovative biopharmaceutical products.

About Legend Capital

Legend Capital, established in April 2001, is a fund management company under Legend Holdings that specializes in early-stage venture capital and growth-stage private equity investments. Over the past two decades, Legend Capital has adhered to international standards and created best practices in fund operations and management. By providing a proactive value-added service system, Legend Capital fosters innovative corporate growth, consistently delivering strong investment returns across multiple sectors while driving industrial advancement and social development in China. With the vision of “becoming an investment firm with global influence,” Legend Capital upholds the core value of “Prosperity with Integrity” and actively fulfills its social responsibilities.